HUA MEDICINE-B (02552) continued its upward momentum with another nearly 6% gain. As of press time, the stock was up 4.81% to HK$3.92, with trading volume reaching HK$40.88 million.

On the news front, HUA MEDICINE released its interim results. During the reporting period, Huatangning sales reached 1.764 million boxes, representing a 108% year-over-year increase, while net sales totaled 217.4 million yuan, up 112% compared to the same period last year. Following the termination of its exclusive promotion service agreement with Bayer, the company recognized one-time deferred revenue of 1.2435 billion yuan, achieving a first-half profit of 1.1839 billion yuan. This marks the company's first profitability during a reporting period, highlighting the significant success of its commercialization transformation.

Additionally, expanded production scale and improved operational efficiency drove gross margin up to 54.2%, an increase of 7.7 percentage points from the previous year, demonstrating a clear positive trend in profitability.

Notably, since taking full control of Huatangning's commercial operations in January 2025, the company has achieved remarkable growth through its independent sales team. With the continued expansion of medical insurance coverage, prescription volumes in secondary and tertiary hospitals have increased substantially, demonstrating outstanding results from complete autonomous commercialization.

Beyond strong performance in the domestic market, HUA MEDICINE is actively expanding its overseas business and accelerating its global expansion strategy. In the R&D sector, the company continues to invest heavily, providing solid support for overseas market development.